drugset / Trial / NCT07110194
Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
Phase 1
Not yet recruiting
75 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.
Timeline
- Start
- 2025-09
- Primary completion
- 2026-03
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2825 | Unknown | — | Subcutaneous |